Archive

By: Dr. Jie Jack Li, Vice President of Discovery Chemistry at ChemPartner   On October 5, 2020, the Nobel Assembly at the Karolinska Institute announced the Nobel Prize for Physiology or Medicine went to Harvey J. Alter, Michael Houghton, and Charles M. Rice “for their discovery of hepatitis C virus (HCV).” The worldwide incidence of […]

By: Dr. Jie Jack Li, Vice President of Discovery Chemistry at ChemPartner On June 16th, 2020, a team at Oxford University announced that their RECOVERY trials had revealed that a daily treatment of 6 mg of dexamethasone (Decadron, 1) lowered the fatality rate of ventilated COVID-19 patients by up to one third! This was a […]

By: Dr. Jie Jack Li, Vice President of Discovery Chemistry at ChemPartner Gileadʹs antiviral drug remdesivir (Veklury, 1) was approved by the FDA on May 1st for emergency use against coronavirus disease-2019 (COVID-19) after just a one-day review. Now the onerous task falls upon Gilead to make enough of the drug to supply doctors and […]

By: Dr. Jie Jack Li, Vice President of Discovery Chemistry at ChemPartner Gileadʹs antiviral drug remdesivir (Veklury) was approved by the FDA on May 1, 2020 for emergency use in coronavirus disease-2019 (COVID-19) patients after a one-day review. It took the Japanese government much longer to give the nod, seven days, before granting its regulatory […]

By: Dr. Jie Jack Li, Vice President of Discovery Chemistry at ChemPartner Gileadʹs antiviral drug remdesivir has been catapulted to the limelight as the only FDA-approved treatment of coronavirus Covid-19 for emergency use thus far. On April 29, 2020, preliminary clinical trials indicated that the drug has shown some efficacy. While mortality rate for patients […]

By: Dr. Manny Ventura, Director and Global Head of Analytical Chemistry at ChemPartner Supercritical fluid chromatography (SFC) is now a well-established tool incorporated into the small molecule drug development strategy for organizations of all types and sizes. Its imprint is almost surely on the history of development of any new advanced chiral drug candidate. Big […]

By: Dr. Kevin Greenman, Principal Scientist at ChemPartner When it comes to finding new chemical matter to engage biological targets, fragment-based screening (FBS) offers a number of advantages over traditional high-throughput screening (HTS). The success of this approach has resulted in a growing list of molecules advancing through clinical trials. From the perspective of a […]

By: Dr. Shireen Khan, Senior Director of Biologics at ChemPartner Through our partnership with single cell technology company Berkeley Lights, Inc., ChemPartner offers the innovative Optofluidic based Beacon® platform at our South San Francisco lab. The nano chip technology of the  Beacon® platform enables  functional characterization of  antibodies secreted from single B cells. The Berkeley […]